SCIENTIA ADVISORS: NEWS
Release Date: 05/29/2008Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian will be a speaker at the Cancer Diagnostics: Next Generation Molecular Technologies, August 21-22, 2008 - Ritz-Carlton Hotel, Washington, D.C.
Issues Discussed:
Cancer is a complex, multi-factorial disease comprising more than 100 similar diseases. Current diagnostic tools, including various blood marker based immuonoassays, imaging techniques, and biopsy analysis, provide valuable information but remain effective only when the tumor frequency is greater than 1% to 10%. New molecular tests such as breast cancer prognosis are changing the cancer care paradigm by providing critically needed information early in the care cycle and reducing healthcare costs. This session focuses on such high value molecular tests for solid tumors that improve disease outcome by providing early detection, prognostic information, and stratify responsiveness to therapy.
www.healthtech.com
Harry Glorikian’s experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia’s clients range from emerging innovators to global market leaders.
Click here to download PDF versionCancer is a complex, multi-factorial disease comprising more than 100 similar diseases. Current diagnostic tools, including various blood marker based immuonoassays, imaging techniques, and biopsy analysis, provide valuable information but remain effective only when the tumor frequency is greater than 1% to 10%. New molecular tests such as breast cancer prognosis are changing the cancer care paradigm by providing critically needed information early in the care cycle and reducing healthcare costs. This session focuses on such high value molecular tests for solid tumors that improve disease outcome by providing early detection, prognostic information, and stratify responsiveness to therapy.
www.healthtech.com
Harry Glorikian’s experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia’s clients range from emerging innovators to global market leaders.
